Physician profile
Andrew Wang
NPI 1417184144
$96,918.58
in general payments reported to CMS, 2019-2025
27 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $120 · 2021: $524 · 2022: $1,919 · 2023: $32K · 2024: $31K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Consulting Fee: $28K · Food and Beverage: $14K · Travel and Lodging: $2,835 · Education: $364 · Grant: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,867.93 |
| Consulting Fee | $27,992.50 |
| Food and Beverage | $13,782.09 |
| Travel and Lodging | $2,835.08 |
| Education | $364.42 |
| Grant | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50,596.97 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $16,196.20 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $9,431.90 | 2019-2025 | |
| Pfizer INC. | $5,324.63 | 2022-2025 | |
| Ucb, INC. | $4,132.17 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $2,980.00 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,459.88 | 2020-2025 | Tremfya |
| Incyte Corporation | $1,259.42 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $991.82 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Celgene Corporation | $939.44 | 2024 | Sotyktu |
| Genzyme Corporation | $650.38 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $582.50 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $329.80 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $228.87 | 2021-2025 | Dupixent |
| Organon LLC | $167.40 | 2025 | Vtama, Hadlima |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $131.78 | 2023-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $90.52 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.22 | 2022-2023 | Spevigo |
| Dermavant Sciences, INC. | $81.63 | 2023-2024 | Vtama |
| Merck Sharp & Dohme LLC | $73.10 | 2023-2024 | Keytruda |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.00 | 2021 | |
| Sandoz INC. | $35.21 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $29.94 | 2023 | Poteligeo |
| Springworks Therapeutics, INC. | $24.70 | 2025 | Gomekli |
| Csl Behring | $23.03 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $16.83 | 2025 | |
| Aclaris Therapeutics, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.